Storied History

LIDE (Lab for Innovated Diagnosis and Experimental Therapeutics) is a translational medicine service provider with 10 years of delivering innovations in oncology translational research and immuno oncology. LIDE was founded in 2011 by overseas returnees Drs. Danyi Wen, Yizhun Zhu, et al, with the goal of bringing together first-class research and management teams with advanced scientific backgrounds to push the frontier of translational medical research. 

LIDE is comprised of three entities.

  • Shanghai LIDE Biotech Co., Ltd. (“LIDE Biotech”) is committed to the research, service and product development of individualized precision medicine for cancer. LIDE Biotech provides traditional CRO services to pharmaceutical companies as well as assisting doctors in the clinical setting to deliver personalized medicine. We own AAALAC accredited SPF level animal centers and world-class equipment. 
  • Shanghai LIWEN Biotech Co., Ltd. (“LIWEN”), founded in 2012, is a third-party testing unit for individualized diagnosis and precision medicine of cancer. Services include: molecular biomarker testing, pathology and companion diagnosis. The company has been certified by the American Association of Pathologists (CAP) with FDA-approved data reporting system and central lab qualifications. Shanghai LIWEN-Promega's Joint Laboratory was founded by Shanghai LIWEN and American Promega which is dedicated to the research and development of Immune Check Point biomarkers (MSI, dMMR, etc.).
  • Xi'an LIDE Biotech Co., Ltd. ("Xi'an LIDE"), founded in 2013, is also an independently operated clinical medical laboratory. It is the public service platform of translational medicine at Xi'an Hi-tech Park, Xi'an LIDE also owns a SPF-level laboratorial animal center with AAALAC accreditation and the medical license of clinical testing lab.